source
- Tris Pharma's CRL for narcolepsy drug; Agenus abandons Phase 3 CRC trialPlus, news about Insilico, Ipsen, Q32 Bio, GSK’s Jemperli, Drug Farm and Padcev. ❌ FDA rejects Tris Pharma’s narcolepsy drug: Its rejection letter said that “additional information will be necessar…Endpoints · 17d ago↗ source
- Biotech startup funding gap widens despite rebound in VC investmentThough funding totals represented the highest first-half sum since the start of 2022, industry watchers are concerned that small startups are being left behind.BioPharma Dive · 17d ago↗ source
- Deals, deals, deals; Biohaven takes on Eli Lilly; and moreWelcome back to Endpoints Weekly! Don’t miss Ryan Cross’ deep dive into the paranoia caused by competition with China. Ryan writes that US biotech companies are holding their cards close to the ...